Developing complex oral therapies requires critical decisions at every stage, from navigating early formulation challenges and accelerating first-in-human studies to managing highly potent compounds and preparing for commercial launch.
Join us for an expert-led seminar exploring how integrated, phase-appropriate strategies can help overcome development challenges, reduce risk, and build a more efficient path from molecule to market.
Through practical insights and real-world considerations, attendees will gain a broader perspective on designing oral drug development programs with speed, scalability, and long-term success in mind.
Featured Sessions & Speakers
From Molecule to FIH: Designing Development Pathways for Complex Oral Therapies
- Dr. Anshul Gupte, RAC Drugs, Vice President, Pharmaceutical Development, PCI Pharma Services
- Dr. Firouz Asgarzadeh, President, OSD Pharmaceutical Solutions LLC
Choosing the Right Solubility Enabling Strategy – a Decision Framework for Complex Molecules
- Rebecca Coutts, Senior Director, Pharmaceutical Development, PCI Pharma Services
- Lieselotte De Smet, Chief Technology Officer, XeDev (Boston, MA)
- TJ Higley, CEO, Microsize (San Diego, CA)
Ultra High Potent Oral Dose Forms — Containment and Manufacturability at Scale
- David O’Connell, Director of Scientific and Technical Affairs, PCI Pharma Services
- Dean Calhoun, President and CEO, Affygility
Building the Path to Launch Early — Integrated Clinical and Commercial Supply for Complex Oral Therapies
- Kevin Kue, Senior Manager, Global Technical Sales, PCI Pharma Services
- Brian Sheridan, VP, Sales, Global Adherence & Clinicals, Westrock